Literature DB >> 9951688

Establishment of a monoclonal antibody to human myeloma cell: relation to chemotherapy and extramedullar infiltration.

N Kuribayashi1, H Hata, H Matsuzaki, M Yoshida, T Sonoki, A Nagasaki, T Kimura, N Harada, K Takatsuki.   

Abstract

Resistance of myeloma cells to melphalan (L-PAM) is a serious problem. To investigate mechanisms of drug resistance, we generated a monoclonal antibody, clone O3, to melphalan-resistant myeloma cells, KHM-11R. Western blot analysis showed that molecular weight of O3 antigen was approximately 90 kDa. Expression of O3 antigen was approximately two times higher in KHM-11R than in parental melphalan sensitive cell line, KHM-11. O3 was preferentially expressed in plasma cell, B-cell, and monocytic cell lines, but not in T-cell lines. Analysis of bone marrow samples from myeloma patients revealed that 13 of 23 samples expressed O3 antigen at various levels, and that O3 antigen expression in patients correlate with preceding chemotherapy, advanced clinical stage and extramedullar invasion of myeloma cells. Furthermore, patients expressing O3 antigen at the time of diagnosis tended to have poor prognosis. The investigation of O3 antigen in myeloma cells will be useful to reveal the pathophysiology of extramedullar invasion and the mechanism of cell killing by melphalan.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9951688     DOI: 10.1007/BF02787208

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  26 in total

1.  CONTINUOUS CULTURE OF HUMAN LYMPHOBLASTS FROM PERIPHERAL BLOOD OF A CHILD WITH ACUTE LEUKEMIA.

Authors:  G E FOLEY; H LAZARUS; S FARBER; B G UZMAN; B A BOONE; R E MCCARTHY
Journal:  Cancer       Date:  1965-04       Impact factor: 6.860

2.  Establishment and characterization of a human histiocytic lymphoma cell line (U-937).

Authors:  C Sundström; K Nilsson
Journal:  Int J Cancer       Date:  1976-05-15       Impact factor: 7.396

3.  Two human myeloma cell lines, amylase-producing KMS-12-PE and amylase-non-producing KMS-12-BM, were established from a patient, having the same chromosome marker, t(11;14)(q13;q32).

Authors:  T Ohtsuki; Y Yawata; H Wada; T Sugihara; M Mori; M Namba
Journal:  Br J Haematol       Date:  1989-10       Impact factor: 6.998

4.  Phagocytic multiple myeloma with disseminated intravascular coagulation.

Authors:  H Matsuzaki; H Hata; T Watanabe; M Takeya; K Takatsuki
Journal:  Acta Haematol       Date:  1989       Impact factor: 2.195

5.  Human myeloma cell line (KHM-4) established from a patient with multiple myeloma associated with hyperammonemia.

Authors:  H Matsuzaki; F Matsuno; M Yoshida; H Hata; K Okazaki; K Takatsuki
Journal:  Intern Med       Date:  1992-03       Impact factor: 1.271

6.  Establishment and characterization of acute B-cell lymphocytic leukemia cell line showing (8;14) and (14;18) chromosome translocation.

Authors:  H Matsuzaki; H Hata; N Asou; H Suzushima; Y Akahoshi; M Yoshida; S Nagakura; T Ishii; I Sanada; K Takatsuki
Journal:  Acta Haematol       Date:  1990       Impact factor: 2.195

7.  P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD.

Authors:  J Epstein; H Q Xiao; B K Oba
Journal:  Blood       Date:  1989-08-15       Impact factor: 22.113

8.  Development and characterization of a melphalan-resistant human multiple myeloma cell line.

Authors:  W T Bellamy; W S Dalton; M C Gleason; T M Grogan; J M Trent
Journal:  Cancer Res       Date:  1991-02-01       Impact factor: 12.701

9.  Myelomonocytic myeloma cell line (LB 84-1).

Authors:  B G Durie; T M Grogan; C Spier; E Vela; V Baum; M A Rodriquez; Y Frutiger
Journal:  Blood       Date:  1989-02-15       Impact factor: 22.113

10.  Establishment and characterization of an amylase-producing human myeloma cell line.

Authors:  H Matsuzaki; H Hata; M Takeya; K Takatsuki
Journal:  Blood       Date:  1988-09       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.